More than 15,000 people — firefighters, military veterans, and airport workers — are waiting for answers in one of the most consequential toxic exposure litigations in American history. The AFFF lawsuit docket inside MDL 2873 holds 15,264 pending cases as of October 1, 2026, yet the landmark bellwether trial that was supposed to begin October 20, 2025 was quietly removed from the calendar and has not been rescheduled as of mid-2026. In a major development, 3M announced a $7.35 billion settlement on November 3, 2026, addressing roughly 99% of current AFFF personal injury claims involving 115,000–120,000 eligible plaintiffs — but no other defendant has followed suit. This article explains exactly where the litigation stands, what caused the delay, and how claimants can begin estimating their potential compensation right now.
What Is the AFFF Lawsuit and Who Is Affected?
Aqueous film-forming foam — commonly called AFFF — is a firefighting suppressant that was originally developed through a collaboration between the U.S. military and 3M, with the underlying chemistry patented as far back as 1965. For decades, AFFF was the standard tool for combating fuel fires at military installations, commercial airports, and training facilities across the country. The problem is that AFFF contains per- and polyfluoroalkyl substances, or PFAS — a class of synthetic compounds that do not break down in the human body or the environment, earning them the nickname “forever chemicals.”
The two most studied PFAS compounds in AFFF are PFOA and PFOS, both of which have been linked by scientific and regulatory bodies to a range of serious illnesses. The Centers for Disease Control and Prevention has identified occupational PFAS exposure as a significant public health concern, particularly for first responders. Recognized injury categories in MDL 2873 currently include kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and liver cancer. Research by the National Cancer Institute found a statistically significant association between PFAS exposure and testicular cancer specifically, while studies consistently show that firefighters carry triple the PFAS blood concentrations of the general population.
The defendants named across the AFFF lawsuit include some of the largest chemical and fire-safety manufacturers in the world: 3M, DuPont de Nemours, Chemours, Tyco Fire Products, Kidde-Fenwal, BASF, and others. The U.S. Department of Defense required military installations to stop using AFFF as of October 1, 2024, and in October 2026 the Senate approved the Yaw-Miller Bill further limiting the use of PFAS in firefighting foam — a legislative signal that lawmakers view the dangers of these chemicals as settled. A 2023 U.S. Geological Survey analysis estimated that as many as 45 percent of all U.S. tap water sources may contain detectable PFAS levels, underscoring just how widespread contamination has become.
The State of MDL 2873: A Record Docket Frozen at a Critical Moment
MDL 2873 was centralized in the U.S. District Court for the District of South Carolina in December 2018, beginning with just 75 cases before Judge Richard M. Gergel. By October 1, 2026, that number has grown to 15,264 pending personal injury cases — the highest caseload the docket has ever carried. The explosive growth is itself one reason the first personal injury bellwether trial was postponed: a surge in new filings in mid-2025 triggered additional administrative processing requirements that Judge Gergel addressed through a September 5, 2025 filing facilitation window, which ordered bundled complaints of up to 150 plaintiffs and standardized short-form complaints to manage the volume.
The bellwether trial that had been scheduled for October 20, 2025, was focused narrowly on kidney cancer claims. That trial was vacated and, as of mid-2026, has not been rescheduled. The absence of a firm trial date removes the most powerful settlement pressure mechanism available in mass tort litigation — the looming prospect of a jury verdict that forces defendants to calculate their exposure. Meanwhile, DuPont de Nemours reported approximately 13,700 personal-injury cases pending against it in the AFFF MDL as of September 30, 2026, and no personal-injury settlement by any AFFF defendant other than 3M has been announced.
Despite the stalled trial calendar, the docket has not been idle. Judge Gergel has continued issuing case management orders refining plaintiff fact sheets, expert discovery deadlines, and defendant-specific litigation tracks. The sheer administrative weight of more than 15,000 individual claims — each requiring its own medical records, occupational history, and exposure documentation — means that behind-the-scenes work is proceeding even when no trial date anchors the public timeline.
The Municipal Settlement Gap: Billions Paid Out — None to Cancer Patients
One of the most striking features of the AFFF litigation as of late 2026 is the stark disparity between settlements reached with public water utilities and the absence of comparable compensation for individual cancer claimants — at least until 3M’s November 2026 announcement. 3M previously reached an $10.3 billion agreement with public water systems, payable over thirteen years, to address PFAS contamination in municipal drinking water supplies. DuPont and its spin-offs Chemours and Corteva reached a separate agreement worth approximately $1.185 billion with water utilities. Those frameworks have been substantially implemented.
The logic behind the sequencing is straightforward: municipal water claims were more uniform, more easily quantified through contamination data, and carried significant regulatory and political risk that incentivized early resolution. Individual personal injury claims are far more fact-intensive — each plaintiff must establish their exposure history, the specific chemicals involved, and a causal link to their particular diagnosis. That complexity has historically caused personal injury tracks in mass torts to lag years behind property or contamination settlements.
That dynamic shifted dramatically on November 3, 2026, when 3M announced a $7.35 billion personal injury settlement, payable over nine years from 2026 through 2034, designed to resolve approximately 99% of current AFFF personal injury claims involving an estimated 115,000 to 120,000 eligible plaintiffs. The settlement represents the first major financial commitment by any AFFF defendant directly to individual cancer patients. However, it also highlights how far the remaining defendants have yet to go: as of the announcement date, no other AFFF manufacturer had reached a comparable personal injury agreement, leaving tens of thousands of claimants against DuPont, Chemours, Tyco, and others still without a resolution framework.
AFFF Settlement Value: What Individual Claims Could Be Worth
Estimating individual AFFF settlement values requires understanding the variables that plaintiffs’ attorneys and defense counsel weigh when evaluating any toxic tort claim. No official settlement grid has been publicly released for the personal injury track as of late 2026, but attorneys working inside MDL 2873 have discussed general valuation frameworks based on comparable mass tort resolutions and the specific injury categories Judge Gergel has designated for bellwether consideration.
The primary drivers of individual claim value are diagnosis type, exposure duration and intensity, plaintiff age and life expectancy, and the availability of documentary proof. Among the recognized injury categories, kidney cancer and testicular cancer claims are generally expected to command the highest individual values because the scientific literature most directly links PFOS and PFOA exposure to those specific malignancies. Thyroid disease and ulcerative colitis claims, while recognized, typically carry lower valuations because the causal pathway is considered less direct and the conditions are more commonly attributable to non-AFFF factors.
Exposure documentation is often the decisive variable separating high-value claims from lower-value ones. A retired military firefighter who trained on live-fire exercises at a base where AFFF was used for twenty years — and who has military service records, base assignment logs, and a confirmed kidney cancer diagnosis — presents a substantially stronger claim than a civilian airport worker with fragmented employment records and a thyroid nodule. Attorneys are advising clients to gather all available occupational records, medical histories, and any PFAS blood test results before submitting plaintiff fact sheets.
Using the 3M settlement as a reference point, the $7.35 billion fund spread across 115,000 to 120,000 eligible claimants produces a rough average of approximately $61,000 to $64,000 per plaintiff before attorney fees and litigation costs — though actual distributions will almost certainly be weighted by injury severity, meaning that kidney and testicular cancer claimants with strong exposure records could receive multiples of that average while claimants with less severe diagnoses receive less. Mass tort settlement matrices in comparable litigations have historically allocated two to five times the base tier amount to the highest-severity cancer categories.
What Happens Next in the AFFF Litigation Timeline
The AFFF litigation enters late 2026 at an inflection point. The 3M personal injury settlement announcement fundamentally changes the landscape: it establishes that individual cancer claims can be resolved on a mass basis, it sets a financial benchmark other defendants will face pressure to match or exceed, and it signals to the broader plaintiff community that compensation is achievable. At the same time, the vacated kidney cancer bellwether and the absence of a rescheduled trial date means that the primary coercive mechanism driving remaining defendants toward settlement — a looming jury verdict — remains absent.
Several developments will shape the litigation’s trajectory into 2027. First, the 3M settlement administration process itself will consume significant judicial and plaintiff leadership resources, as an estimated 115,000 to 120,000 claimants must be evaluated for eligibility and placed into compensation tiers. That administrative burden could slow the broader docket. Second, Judge Gergel will need to decide whether to reschedule the kidney cancer bellwether or select a different injury category — potentially testicular cancer — as the next trial focus. The selection will signal which defendants face the most immediate trial pressure. Third, DuPont’s approximately 13,700 pending personal injury cases represent a substantial unresolved liability that the company has not yet moved to settle, and the pressure created by both the 3M settlement benchmark and any rescheduled bellwether will intensify scrutiny of DuPont’s litigation posture heading into 2027.
Legislatively, the Senate’s October 2026 approval of the Yaw-Miller Bill restricting PFAS in firefighting foam adds another layer of pressure on manufacturers to resolve outstanding claims before additional regulatory developments further solidify the government’s position on PFAS dangers. Attorneys expect that the combination of the 3M settlement precedent, ongoing bellwether scheduling decisions, and the evolving regulatory environment will drive meaningful activity in the remaining defendant tracks throughout 2027.
For individual claimants, the practical implication is clear: the litigation is moving toward resolution, but the path runs through administrative processes and negotiation tracks that reward early, well-documented claim submissions. Claimants who have not yet filed, or who filed without complete supporting documentation, should work with qualified mass tort counsel now to ensure their plaintiff fact sheets are complete and accurately reflect both their exposure history and the full scope of their diagnosed injuries.
Frequently Asked Questions About the AFFF Lawsuit in 2026
Why was the October 2025 AFFF bellwether trial canceled, and when will it be rescheduled?
The kidney cancer bellwether trial that had been scheduled to begin October 20, 2025, was removed from the calendar following a surge in new case filings that required Judge Gergel to issue a filing facilitation order in September 2025. The order imposed bundled complaint requirements and standardized short-form complaints to manage the administrative volume created by thousands of new plaintiffs entering the docket simultaneously. As of mid-2026, the vacated kidney cancer bellwether has not been rescheduled, and no replacement date has been announced. Judge Gergel retains discretion to either reschedule the kidney cancer trial or pivot to a different injury category, such as testicular cancer, as the next bellwether focus. The absence of a trial date significantly reduces settlement pressure on defendants who have not yet reached personal injury agreements.
Who qualifies to file an AFFF lawsuit claim in 2026?
Potential claimants generally include military firefighters, civilian airport firefighters, industrial firefighters, and others who had documented occupational exposure to AFFF for a meaningful duration, as well as individuals who lived or worked near military bases or airports where AFFF was regularly used and who consumed contaminated water over an extended period. The recognized injury categories in MDL 2873 include kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and liver cancer. Statutes of limitations vary by state and begin running from the date of diagnosis or the date a claimant knew or reasonably should have known of the connection between their illness and AFFF exposure — making prompt legal consultation essential for anyone who believes they may qualify.
Have any AFFF settlements paid money to individual cancer patients yet?
Prior to November 2026, all major AFFF settlements — including 3M’s $10.3 billion water utility agreement and DuPont’s $1.185 billion water utility settlement — were directed exclusively at public water systems, not individual cancer patients. That changed on November 3, 2026, when 3M announced a $7.35 billion personal injury settlement covering an estimated 115,000 to 120,000 eligible claimants, payable over nine years from 2026 through 2034. As of that announcement, no other AFFF defendant had reached a comparable personal injury settlement, meaning claimants against DuPont, Chemours, Tyco, and other remaining defendants are still awaiting resolution of their individual claims.
How much could an individual AFFF lawsuit settlement be worth?
No public compensation grid has been released for the personal injury track as of late 2026. Using the 3M settlement as a reference, the $7.35 billion fund divided across 115,000 to 120,000 claimants yields a rough average of approximately $61,000 to $64,000 per plaintiff before fees and costs — but actual awards will be weighted by injury severity and exposure documentation. Kidney cancer and testicular cancer claimants with strong occupational records are expected to receive substantially above-average distributions, while claimants with less severe diagnoses or weaker exposure evidence will likely receive less. Comparable mass tort settlement matrices have historically allocated two to five times the base tier amount to the highest-severity categories. Individual case value ultimately depends on diagnosis type, exposure duration and intensity, available documentation, and the specific defendant against whom the claim is asserted.
What should AFFF claimants do while waiting for the bellwether to be rescheduled?
Claimants should use the current period to strengthen their claim files rather than waiting passively. That means gathering all available military service records, employment records, base or airport assignment documentation, PFAS blood test results, and complete medical records related to their diagnosis. Claimants who have not yet worked with a qualified mass tort attorney should do so promptly, both to protect against statute of limitations issues and to ensure that their plaintiff fact sheets — the foundational documents the court and defendants use to evaluate individual claims — are complete and accurate. Attorneys experienced in MDL 2873 can also advise claimants on whether they may be eligible under the 3M settlement framework and what steps are required to preserve claims against defendants who have not yet settled.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.